Literature DB >> 1372650

Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation.

R P Johnson1, A Trocha, T M Buchanan, B D Walker.   

Abstract

Although the immunologic basis of protective immunity in human immunodeficiency virus type 1 (HIV-1) infection has not yet been defined, virus-specific cytotoxic T lymphocytes (CTL) are likely to be an important host defense and may be a critical feature of an effective vaccine. These observations, along with the inclusion of the HIV-1 envelope in the majority of vaccine candidates presently in clinical trials, underscore the importance of the precise characterization of the cellular immune responses to this protein. Although humoral immune responses to the envelope protein have been extensively characterized, relatively little information is available regarding the envelope epitopes recognized by virus-specific CTL and the effects of sequence variation within these epitopes. Here we report the identification of two overlapping CTL epitopes in a highly conserved region of the HIV-1 transmembrane envelope protein, gp41, using CTL clones derived from two seropositive subjects. An eight-amino acid peptide was defined as the minimum epitope recognized by HLA-B8-restricted CTL derived from one subject, and in a second subject, an overlapping nine-amino acid peptide was identified as the minimal epitope for HLA-B14-restricted CTL clones. Selected single amino acid substitutions representing those found in naturally occurring HIV-1 isolates resulted in partial to complete loss of recognition of these epitopes. These data indicate the presence of a highly conserved region in the HIV-1 envelope glycoprotein that is immunogenic for CTL responses. In addition, they suggest that natural sequence variation may lead to escape from immune detection by HIV-1-specific CTL. Since the region containing these epitopes has been previously shown to contain an immunodominant B cell epitope and also overlaps with a major histocompatibility complex class II T cell epitope recognized by CD4+ CTL from HIV-1 rgp160 vaccine recipients, it may be particularly important for HIV-1 vaccine development. Finally, the identification of minimal CTL epitopes presented by class I HLA molecules should facilitate the definition of allele-specific motifs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372650      PMCID: PMC2119173          DOI: 10.1084/jem.175.4.961

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  59 in total

1.  Cellular peptide composition governed by major histocompatibility complex class I molecules.

Authors:  K Falk; O Rötzschke; H G Rammensee
Journal:  Nature       Date:  1990-11-15       Impact factor: 49.962

2.  Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule.

Authors:  G M Van Bleek; S G Nathenson
Journal:  Nature       Date:  1990-11-15       Impact factor: 49.962

3.  General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.

Authors:  R A Houghten
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

4.  Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus.

Authors:  J W Gnann; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

5.  The evolutionary dynamics of HIV-1 quasispecies and the development of immunodeficiency disease.

Authors:  M A Nowak; R M May; R M Anderson
Journal:  AIDS       Date:  1990-11       Impact factor: 4.177

6.  HIV infection. Why the long latent period?

Authors:  C R Bangham; A J McMichael
Journal:  Nature       Date:  1990-11-29       Impact factor: 49.962

7.  High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals.

Authors:  F M Gotch; D F Nixon; N Alp; A J McMichael; L K Borysiewicz
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

8.  Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.

Authors:  E L Cooney; A C Collier; P D Greenberg; R W Coombs; J Zarling; D E Arditti; M C Hoffman; S L Hu; L Corey
Journal:  Lancet       Date:  1991-03-09       Impact factor: 79.321

9.  Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells.

Authors:  S A Hammond; E Obah; P Stanhope; C R Monell; M Strand; F M Robbins; W B Bias; R W Karr; S Koenig; R F Siliciano
Journal:  J Immunol       Date:  1991-03-01       Impact factor: 5.422

10.  Recognition of influenza A matrix protein by HLA-A2-restricted cytotoxic T lymphocytes. Use of analogues to orientate the matrix peptide in the HLA-A2 binding site.

Authors:  F Gotch; A McMichael; J Rothbard
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

View more
  45 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection.

Authors:  G W Nelson; R Kaslow; D L Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

3.  Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection.

Authors:  J Dorn; S Masciotra; C Yang; R Downing; B Biryahwaho; T D Mastro; J Nkengasong; D Pieniazek; M A Rayfield; D J Hu; R B Lal
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 4.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

5.  Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development.

Authors:  H Cao; P Kanki; J L Sankalé; A Dieng-Sarr; G P Mazzara; S A Kalams; B Korber; S Mboup; B D Walker
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  Prediction of an HLA B8-restricted influenza epitope by motif.

Authors:  A Suhrbier; C Schmidt; A Fernan
Journal:  Immunology       Date:  1993-05       Impact factor: 7.397

7.  Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-alpha), and TNF-beta when they encounter their target antigens.

Authors:  C Jassoy; T Harrer; T Rosenthal; B A Navia; J Worth; R P Johnson; B D Walker
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

8.  Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses.

Authors:  L E Brown; D O White; C Agius; B E Kemp; N Yatzakis; P Poumbourios; D A McPhee; D C Jackson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2.

Authors:  B Wizel; R A Houghten; K C Parker; J E Coligan; P Church; D M Gordon; W R Ballou; S L Hoffman
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

10.  Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes.

Authors:  S Chada; C E DeJesus; K Townsend; W T Lee; L Laube; D J Jolly; S M Chang; J F Warner
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.